QP 22 - Refining Prostate Cancer Care: Integration, Innovation, and Outcomes

Presentations

• 05:00pm - 05:05pm ET

  Introductions

  Speaker: Sagar Patel, MD - Emory University, Atlanta
• 05:05pm - 05:10pm ET

  Duration of Androgen Receptor Pathway Inhibitor and ADT with Metastasis Directed Therapy In Oligometastatic Cancer of the Prostate (DIRECT): A Phase 2 Randomized Trial

  Speaker: Rachel Glicksman, MD - University of Toronto, Toronto
• 05:10pm - 05:15pm ET

  MR-Linac Based Prostate SBRT with Simultaneous Integrated Boost to Dominant Index Lesions: Early Results of a Prospective Multicenter Phase II Trial

  Speaker: Magali Quivrin, MD - Centre Georges François LECLERC, Dijon
• 05:15pm - 05:20pm ET

  Multicenter MRI-Only vs. CT planning for Prostate Cancer: Implementation, Dosimetry and One-Year Quality of Life Outcomes

  Speaker: Tony Young, MD, PhD - Institute of Medical Physics, School of Physics, University of Sydney,, Sydney
• 05:20pm - 05:25pm ET

  Differential Association of Post-Testosterone Recovery PSA Kinetics with Progression and Metastatic Outcomes In Prostate Cancer

  Speaker: Soumyajit Roy, MBBS, MSc. - University Hospitals Seidman Cancer Center, Cleveland
• 05:25pm - 05:30pm ET

  Lower Mean Penile Bulb Dose Correlates with Better 48-Month Sexual QOL in a Randomized Rectal Spacer Trial

  Speaker: Daniel Song, MD - Johns Hopkins University, Baltimore
• 05:30pm - 05:35pm ET

  Functional Radiosensitivity Assay Identifies Immune Markers Associated with Late Rectal Bleeding after Prostate Radiotherapy: The TransPROUST Study

  Speaker: Kamel Debbi, MD, PhD - CHU Henri Mondor, Creteil
• 05:35pm - 05:55pm ET

  Questions & Answers

  Speaker: Mutlay Sayan, MD - Brigham and Women's Hospital/Dana-Farber, Boston
• 05:55pm - 06:00pm ET

  Closing

  Speaker: Sagar Patel, MD - Emory University, Atlanta